RABISIN displays consistent high potent glycoprotein G level as tested by ELISA test at release

Authors: Thaïs Vila[1], Anne-Laure Dagonneau[1], Jean-Philippe Tronel[1]
[1]Boehringer-Ingelheim Animal Health, Lyon, France

INTRODUCTION

- Importance of using high-quality rabies vaccines to achieve the goal of Zero by 30.
- **First** in vitro ELISA test able to quantify the rabies glycoprotein G antigen in RABISIN formulated vaccine was developed as an alternative to NIH potency test in 2015[1].
- ELISA titration results of recent batches of RABISIN produced in 2023 are presented

METHODS

- Glycoprotein G is the primary antigen that stimulates virus-neutralizing antibody production (immunity) against rabies virus infection.
- Quantity of glycoprotein G of RABISIN® measured to ensure the highest quality in terms of immunogenicity
- Key advantages
  - ✓ specificity
  - ✓ robustness



- 19 batches of RABISIN® produced in 2023 tested by ELISA

RESULTS



- Best alternative to NIH:
  - ✓ Animal welfare
  - ✓ More discriminant to confirm batch-to-batch consistency,
  - ✓ Safety benefit for laboratory staff
  - ✓ Lead-time to market significantly reduced

CONCLUSION

High potent glycoprotein G quantity for RABISIN and batch to batch consistency

References:
1. C. Sigoillot-Claude *et al*. A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine, Vaccine, Volume 33, Issue 32, 2015, Pages 3843-3849,

Thais.vila@boehringer-Ingelheim.com